Biologics for pediatric atopic dermatitis

A protocol of A systematic review and meta-analysis

Rui Cao, MM¹⁺, Jiaxing Lu, MM¹⁺, Zhao Chen, MD²,*

¹. North China University of Science and Technology, Hebei Tangshan, China.
². Tangshan Gongren Hospital, Hebei Tangshan, China.

*Correspondence: Zhao Chen, Relixueyuan, Weiguobeilu Street, Tangshan, Hebei, 063000, China. (Email: liasandeno@163.com)

† Rui Cao, and Jiaxing Lu contributed equally to this manuscript

Abstract

Background: Atopic dermatitis is a common chronic pruritic inflammatory skin disease, tends to occur in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with Biologics, as biologics continue to emerge for atopic dermatitis (AD).

Methods: The databases we will search include Embase, Cochrane Library, Web of Science, the and PubMed of RCTs from inception to 15th May 2022. The primary outcomes are the proportion of patients with EASI 75 as the primary outcome. The secondary outcomes include NRS, DLQI score and adverse reaction incidence. Studies will be screened by two independent authors. They will assess the risk of bias of the final included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
RevMan 5.3 software.

**Results:** The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis.

**Conclusion:** We aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis and provide evidence-based data for clinical application

**Ethics and dissemination:** The study does not collect raw data and personal information, does not involve jeopardizing the rights of the participants. Ethical approval was not required. The results may be reported in publications and the media

**PROSPERO registration number:** CRD42022319052 (https://www.crd.york.ac.uk/PROSPERO/#joinuppage)

**Abbreviations:** AD: atopic dermatitis; RCT: randomized controlled trial; SMD: Standard Mean Difference; RR: risk ratio; CI: confidence interval; EASI: Eczema Area and Severity Index; DLQI: Dermatology Life Quality Index; NRS: Numerical Rating Scale.  

**Keywords:** meta-analysis protocol, Biologics, pediatric atopic dermatitis

**1. Introduction:** Atopic dermatitis is a common chronic pruritic inflammatory skin disease. AD prevalence is increasing in all ages, in the US 10% of adults and 13% of children have AD[1,2]. Chronic itchy skin caused by AD can have a serious impact on patients' quality of life [3,4]. In
recent years, studies on the pathogenesis of atopic dermatitis have found that the activation of Th2-type inflammation-related pathways and its driving factors IL-4, IL-13 and IL-31 and the increase of inflammatory dendritic epidermal cells are the basic factors of atopic dermatitis. Such research has led to the development of biologics for the treatment of AD\[5,6\]. However, there is a lack of systematic reviews for pediatric atopic dermatitis. The aim of our meta-analysis is to provide data supporting the clinical application of biologics in treating pediatric atopic dermatitis.

2. Methods:

This systematic review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PROSPERO has accepted this protocol for review, with registration number CRD42022319052.

2.1. Eligibility criteria

2.1.1. Types of study: There will be a search for all randomized controlled trials (RCTs) evaluating the efficacy and safety of biologics for treating pediatric atopic dermatitis. Study types such as non-RCTs and animal mechanism studies will be excluded from the review.

2.1.2. Types of participants: Patients with atopic dermatitis range in age from 6 to 18 years old, regardless of gender, the severity of their condition and nationality.
2.1.3. Types of interventions: Experimental patients received a biologic with or without other drugs, and control patients received a placebo or non-biologic treatment.

2.2. Measurement of outcomes:

2.2.1. Primary outcomes: The primary outcome is the percentage of patients who improved their EASI score from baseline by 75% or more (EASI 75) based on the rate of decline in the Eczema Area and Severity Index (EASI) score.

2.2.2. Secondary outcomes: According to the evaluation standard, the Dermatology Life Quality Index (DLQI), the Numerical Rating Scale (NRS), and adverse reaction incidence are evaluated as secondary outcomes.

2.3. Electronics searches: Embase, Cochrane Library, Web of Science, the and PubMed will be searched from inception to 15th May 2022 to collect RCTs of biologics used to treat pediatric atopic dermatitis. Besides, English is the limitation of language. Table 1 show the Search strategy in PubMed.

2.4. Search strategy: Keywords include “Atopic Dermatitis”, “Atopic Neurodermatitis”, “Upadacitinib”, “abrocitinib”, “lebrikizumab”, “dupilumab” and ”randomized controlled trial” etc.

2.5. Data collection and analysis: Study titles, abstracts, and full texts will be independently reviewed by two researchers (CaoRui and
LuJiaxing). We will record the reasons for excluding RCTs. Any disagreements will be settled by a third researcher (ChenZhao). Figure 1 illustrates the study selection process.

2.6. Risk of bias assessment: Each trial will be evaluated independently by two researchers (CaoRui and LuJiaxing) according to the Cochrane Risk of Bias Tool. We assessed random sequence generation, allocation concealment, blinding of intervention, blinding of outcome assessment, reporting of outcome data complete, and selective reporting and other biases.

There are 3 levels of study bias: high risk, low risk, and unclear risk.

2.7. Data Synthesis and Statistical Analysis: We will conduct the meta-analysis using RevMan V.5.3.0. Continuous data are expressed as standardized mean difference (SMD) with 95% confidence intervals. Dichotomous data will be assessed using the risk ratio (RR) with 95% CIs.

2.7.1. Assessment of heterogeneity: To determine statistical heterogeneity, we will calculate $I^2$ or use Chi-Square tests. It will be viewed as low or no heterogeneity if $I^2 < 50\%$, while $I^2 \geq 50\%$ will be viewed as significant heterogeneity among the trials. In that case, we will conduct a sensitivity or subgroup analysis to identify possible sources of heterogeneity.
2.7.2. **Subgroup analysis**: If there is sufficient studies, subgroup analysis will be conducted according to different types of biologics, Age range of trial Participants, treatment frequency, or treatment course.

2.7.3. **Sensitivity analysis**: Sensitivity analyses will be performed to check whether results are robust and reliable, based on methodological quality, sample size, statistical models, and missing data.

2.7.4. **Assessment of publication bias**: The publication bias will be assessed with funnel plots if more than 10 studies are included in the meta-analysis. The asymmetry of funnel plot will be checked by egger test.

2.7.5. **Evidence quality evaluation**: The quality of evidence will be categorized as high, moderate, low, or very low, based on GRADE.

3. **Discussion**: Atopic dermatitis (AD) is a chronic inflammatory skin disease in children and adults. AD can be adequately managed with topical therapies, gentle skin care practices [7]. For severe AD, phototherapy, biological agents, and systemic immunosuppressants can be combined [8,9]. Dupilumab, as a fully human IL-4Rα monoclonal antibody, can inhibit Th2-mediated inflammatory response by targeting IL-4 and IL-13 [10,11]. Tralokinumab and Lebrikizumab are humanized immunoglobulin IgG4 monoclonal antibodies. It inhibits the signaling pathway mediated by IL-13Rα1/IL-4Rα complex through binding to the IL-13α receptor [12]. Omalizumab is a monoclonal antibody drug for childhood allergy. It interrupts the IgE-dependent allergic inflammatory
cascade by binding to free IgE and preventing it from binding to IgE receptors [13]. Etokimab is a human monoclonal IgG1 antibody that neutralizes IL-33. Preliminary clinical studies are currently reported in AD, and asthma[14]. In addition, there are case reports or I/II clinical trials of fezakinumab, nemolizumab, tezepelumab, Secukinumab, GBR 830 and recombinant interferon-γ for AD treatment, which are expected to be used in the treatment of other atopic comorbidities in the future[15]. This meta-analysis systematically evaluated the efficacy and safety of biologics by including a randomized, placebo-controlled study of dupilumab in the treatment of children with atopic dermatitis, and provided reference for clinical treatment.

**Author contributions**

Conceptualization: Rui Cao, Zhao Chen.

Investigation: Rui Cao, Jiaxing Lu.

Supervision: Zhao Chen.

Writing – original draft: Rui Cao.

Writing – review & editing: Zhao Chen, Jiaxing Lu.

**Funding**

This study was not funded.

**Competing interests**

None declared.

**Patient consent for publication**
Not required

References


Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP)[J/OL]. Italian Journal of Dermatology and Venereology, 2021, 156(2): 184-197. https://doi.org/10.23736/S2784-8671.20.06654-7.


Figure 1
### Search strategy in PubMed

<table>
<thead>
<tr>
<th>Number</th>
<th>Search items</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Atopic Dermatitis[Mesh]</td>
</tr>
<tr>
<td>2</td>
<td>Atopic Dermatitis[Title/Abstract]</td>
</tr>
<tr>
<td>3</td>
<td>Atopic Dermatitis[Title/Abstract]</td>
</tr>
<tr>
<td>4</td>
<td>Dermatitis, Atopic[Title/Abstract]</td>
</tr>
<tr>
<td>5</td>
<td>Neurodermatitis, Atopic[Title/Abstract]</td>
</tr>
<tr>
<td>6</td>
<td>Atopic Neurodermatitis[Title/Abstract]</td>
</tr>
<tr>
<td>7</td>
<td>Atopic Neurodermatitis[Title/Abstract]</td>
</tr>
<tr>
<td>8</td>
<td>Neurodermatides, Atopic[Title/Abstract]</td>
</tr>
<tr>
<td>9</td>
<td>Neurodermatitis, Disseminated[Title/Abstract]</td>
</tr>
<tr>
<td>10</td>
<td>Disseminated Neurodermatitis[Title/Abstract]</td>
</tr>
<tr>
<td>11</td>
<td>Disseminated Neurodermatitis[Title/Abstract]</td>
</tr>
<tr>
<td>12</td>
<td>Neurodermatides, Disseminated[Title/Abstract]</td>
</tr>
<tr>
<td>13</td>
<td>Eczema, Atopic[Title/Abstract]</td>
</tr>
<tr>
<td>14</td>
<td>Atopic Eczema[Title/Abstract]</td>
</tr>
<tr>
<td>15</td>
<td>Eczema, Infantile[Title/Abstract]</td>
</tr>
<tr>
<td>16</td>
<td>Infantile Eczema[Title/Abstract]</td>
</tr>
<tr>
<td>17</td>
<td>1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 10</td>
</tr>
<tr>
<td>18</td>
<td>Lebrikizumab[Title/Abstract]</td>
</tr>
<tr>
<td>19</td>
<td>Omalizumab[Title/Abstract]</td>
</tr>
<tr>
<td>20</td>
<td>Tralokinumab[Title/Abstract]</td>
</tr>
<tr>
<td>21</td>
<td>Etokimab[Title/Abstract]</td>
</tr>
<tr>
<td>22</td>
<td>Dupilumab[Title/Abstract]</td>
</tr>
<tr>
<td>23</td>
<td>18 OR 19 OR 20 OR 21 OR 22</td>
</tr>
<tr>
<td>24</td>
<td>Randomized controlled trial[Title/Abstract]</td>
</tr>
<tr>
<td>25</td>
<td>Controlled clinical trial [Title/Abstract]</td>
</tr>
<tr>
<td>26</td>
<td>Randomized [Title/Abstract]</td>
</tr>
<tr>
<td>27</td>
<td>Randomly [Title/Abstract]</td>
</tr>
<tr>
<td>28</td>
<td>Clinical Trials [Title/Abstract]</td>
</tr>
<tr>
<td>29</td>
<td>24 OR 25 OR 26 OR 27 OR 28</td>
</tr>
<tr>
<td>30</td>
<td>17 AND 23 AND 29</td>
</tr>
</tbody>
</table>